The estimated Net Worth of Michael Messinger is at least $628 millier dollars as of 13 December 2019. Mr Messinger owns over 5,000 units of ContraFect Corp stock worth over $4,425 and over the last 10 years he sold CFRX stock worth over $0. In addition, he makes $623,296 as Chief Financial Officer at ContraFect Corp.
Mr has made over 2 trades of the ContraFect Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CFRX stock worth $1,850 on 13 December 2019.
The largest trade he's ever made was buying 5,000 units of ContraFect Corp stock on 13 December 2019 worth over $1,850. On average, Mr trades about 387 units every 58 days since 2014. As of 13 December 2019 he still owns at least 19,091 units of ContraFect Corp stock.
You can see the complete history of Mr Messinger stock trades at the bottom of the page.
Michael Messinger CPA, CPA is the Chief Financial Officer at ContraFect Corp.
As the Chief Financial Officer of ContraFect Corp, the total compensation of Mr CPA at ContraFect Corp is $623,296. There are 6 executives at ContraFect Corp getting paid more, with Roger Pomerantz having the highest compensation of $1,875,610.
Mr CPA is 46, he's been the Chief Financial Officer of ContraFect Corp since . There are 15 older and 1 younger executives at ContraFect Corp. The oldest executive at ContraFect Corp is Sol Barer, 72, who is the Lead Independent Director.
Michael's mailing address filed with the SEC is C/O CONTRAFECT CORPORATION, 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY, 10701.
Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz et Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
ContraFect Corp executives and other stock owners filed with the SEC include: